Our Latest News - BUHLMANN

BUHLMANN News

Evaluation of BÜHLMANN fPELA® turbo on cobas® c501 at Medical Laboratory Center Dr. Risch

Interview from a laboratory with 14 satellite lab centers, that successfully evaluated the BÜHLMANN fPELA® turbo test. Continue Reading: We can recommend the BÜHLMANN fPELA® turbo due to the easy sample preparation leading to more stable extracts. The analysis with the cobas or a similar system is more flexible, more cost efficient and faster than
Continue Reading

Buhlmann – Next Generation Food Allergy Drug Development Summit

Next Generation Food Allergy Drug Development Summit, July 20-22, 2021: BUHLMANN is proud to partner with this event, specifically focused on enhancing the food allergy drug development approach. Flow CAST® is the standardized, proven & assessable Basophil Activation Test. An accurate biomarker of an allergic reaction… in a vial. BUHLMANN Allergy Assay Offering Diagnosis of
Continue Reading

Digestive Disease Week 2021

Assays Offerings We offer the broadest fecal calprotectin (fCAL) product range in the industry, available in the United States, including FDA cleared and Research Use Only (RUO) kits. These fCAL related tests include FDA 510(k) cleared BÜHLMANN fCAL® ELISA, BÜHLMANN fCAL® turbo & CALEX® Cap; FDA exempt BÜHLMANN fPELA® turbo (Pancreatic Elastase); Tests available as
Continue Reading

Visit BUHLMANN at AACC 2021 (LIVE)

Assays Offerings We offer the broadest fecal calprotectin (fCAL) product range in the industry, available in the United States, including FDA cleared and Research Use Only (RUO) kits. These fCAL related tests include FDA 510(k) cleared BÜHLMANN fCAL® ELISA, BÜHLMANN fCAL® turbo & CALEX® Cap; FDA exempt BÜHLMANN fPELA® turbo (Pancreatic Elastase); Tests available as
Continue Reading

Automate fecal Calprotectin and Pancreatic Elastase assay testing, with BÜHLMANN fCAL® turbo & fPELA® turbo US IVD application

BÜHLMANN fCAL® turbo or BÜHLMANN fPELA® turbo BÜHLMANN fCAL® turbo or BÜHLMANN fPELA® turbo currently have validated IVD application notes for use in the United States on the clinical chemistry analyzers listed below. These allow for the FDA 510(k) cleared fecal calprotectin or FDA Exempt fecal pancreatic elastase to be tested on the Roche cobas®
Continue Reading

LabSense News Q1 2021 Edition

In this "Q1 2021 Edition" we introduced the new fCAL turbo and fPELA application notes (eg. Vitros 5600, cobas® 501, AU480, ADVIA® and Atellica, to name a few). We also introduce the transfer of the founding Melatonin assays and highlight some significant publications to evolve food allergy testing and IBD testing with fecal calprotectin and
Continue Reading

BUHLMANN Diagnostic Corp – New Partner Channel Agreement with Roche Diagnostics

BUHLMANN Diagnostic Corp – New Partner Channel Agreement with Roche Diagnostics.

Continue Reading

LabSense News Q3 2020 Edition

In this “Q3 2020 Edition” we introduce two NEW BUHLMANN Products. The new FDA Exempt, fecal Pancreatic Elastase (fPELA®) turbo assay, as well newly developed Quantum Blue® 3 Reader (QB3).  Also watch the IBDoc® video ‘Want to improve care for IBD patients?’ and lastly watch Dr. Arne Roseth’s AMLI presentation “The latest on IBD Care
Continue Reading

Educational Webinar recording from AMLI presentation by Dr Arne Roseth

BÜHLMANN fCAL® ELISA is FDA 510(k) cleared.  For in vitro Diagnostic Use. Health Canada License: 80726 Abstract Inflammatory Bowel Disease (IBD) is a chronic inflammatory disease of the gut, which presents with periods of inflammatory activity (flares) and quiescent phases (remission) as can be seen in many chronic diseases. IBD includes several different diseases; the two most important
Continue Reading

BÜHLMANN anti-MAG autoantibodies ELISA Citations

US: BÜHLMANN GanglioCombi™ ELISA is for Research Use Only. Not for use in diagnostic procedures. Health Canada Licence: 100436 and 100476 The citation list should be used for information only. Van den Bergh, P.Y.K., et al., 2021: European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of
Continue Reading